Expression of the retinoblastoma-related gene Rb2/p130 in the pathogenesis of serous carcinoma of the ovary

Worley MJ Jr, Michael J. Worley, Charles N Landen, Landen CN, Slomovitz BM, Brian M. Slomovitz, Anais Malpica, Malpica A, Shana L Palla, Palla SL, Ramirez PT, Pedro T Ramirez
Applied immunohistochemistry & molecular morphology : AIMM · 2010 · vol. 18(6) , pp. 509–11 · doi:10.1097/pai.0b013e3181e78fe0 · PMID:20661130
Observational OA: closed
Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-01 ⓘ

This study analyzed 76 ovarian tumors to find that Rb2/p130 expression loss is rare in benign serous cystadenomas but significantly increases during progression to low-grade serous carcinoma.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-22 · read from full text ⓘ

This study evaluated the immunohistochemical expression of the retinoblastoma-related gene Rb2/p130 across a spectrum of seventy-six ovarian tumors ranging from benign cystadenomas to high-grade serous carcinomas. The researchers observed that loss of Rb2/p130 expression was absent in benign cases but occurred in ten percent of serous borderline tumors and forty-seven percent of low-grade serous carcinomas. The analysis identified a significant difference in expression levels during the progression from benign lesions to low-grade malignancy, indicating that decreased gene expression is associated with this specific transition. This paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

OBJECTIVE: The purpose of this study was to evaluate the immunohistochemical Rb2/p130 expression in a series of benign, borderline, and malignant ovarian tumors. STUDY DESIGN: Seventy-six operative specimens were analyzed. Frequencies and percents were calculated for variables by each of the 5 disease stage groups in increasing severity and again for the disease stage groups collapsed into benign (serous cystadenoma or endosalpingosis), low-grade [serous borderline tumors (SBT) or low-grade serous carcinoma (LGSC)] and high-grade serous carcinoma. RESULTS: There was no loss of expression in benign serous cystadenomas (0/18). Ten percent of SBT's (2/20), 47% of LGSC's (9/19), and 16% of HGSC's (3/16) had loss of expression. There was a significant difference in the expression during the progression from cystadenoma to SBT to LGSC. CONCLUSIONS: Loss of Rb2/p130 expression is a rare event in benign cystadenoma. The progression to LGSC is associated with a decrease in gene expression.
Full text 1,212 characters · extracted from oa-doi-fallback · 3 sections · click to expand

Objective

The purpose of this study was to evaluate the immunohistochemical Rb2/p130 expression in a series of benign, borderline, and malignant ovarian tumors. Study Design Seventy-six operative specimens were analyzed. Frequencies and percents were calculated for variables by each of the 5 disease stage groups in increasing severity and again for the disease stage groups collapsed into benign (serous cystadenoma or endosalpingosis), low-grade [serous borderline tumors (SBT) or low-grade serous carcinoma (LGSC)] and high-grade serous carcinoma.

Results

There was no loss of expression in benign serous cystadenomas (0/18). Ten percent of SBT's (2/20), 47% of LGSC's (9/19), and 16% of HGSC's (3/16) had loss of expression. There was a significant difference in the expression during the progression from cystadenoma to SBT to LGSC.

Conclusions

Loss of Rb2/p130 expression is a rare event in benign cystadenoma. The progression to LGSC is associated with a decrease in gene expression.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

MeSH descriptors

Acetylglucosamine Acetylglucosamine Acetylglucosamine Acetylglucosamine Biomarkers, Tumor Biomarkers, Tumor Biomarkers, Tumor Biomarkers, Tumor Carcinoma Carcinoma Cystadenoma Cystadenoma Glioblastoma Glioblastoma Lectins Lectins Membrane Glycoproteins Membrane Glycoproteins N-Acetylglucosaminyltransferases Ovarian Neoplasms

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-11T09:27:45.537177+00:00
pubmed
last seen: 2026-10-08T21:07:47.794683+00:00
unpaywall
last seen: 2026-10-11T06:28:45.473802+00:00